Home » Santarus Submits IND for Phase III Testing of Rifamycin in Travelers’ Diarrhea
Santarus Submits IND for Phase III Testing of Rifamycin in Travelers’ Diarrhea
Santarus, Inc., a specialty biopharmaceutical company,
announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration requesting approval to begin a Phase
III clinical program evaluating rifamycin SV MMX in patients with travelers’ diarrhea.
Fox Business
Fox Business
Upcoming Events
-
07May
-
14May
-
30May